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Highlights 
 Reactive oxygen species (ROS) delivered by engineered honey or gel. 
 Novel antimicrobial with activity against all bacteria as well as antifungal and 
antiviral activity. 
 Topical treatment with antibiofilm activity. 
 Therapeutic implications for wound healing and possibly mucosal infection in 
respiratory and urinary tract. 
 Topical and local applications but could be applied to internal mucosal structures. 
 
 
 
 ABSTRACT 
Reactive oxygen species (ROS) is a novel therapeutic strategy for topical or local 
application to wounds, mucosa or internal structures where there may be heavy 
bacterial bioburden with biofilm and chronic inflammation. Bacterial biofilms are a 
significant problem in clinical settings owing to their increased tolerance towards 
conventionally prescribed antibiotics and their propensity for selection of further 
antibacterial resistance. There is therefore a pressing need for the development of 
alternative therapeutic strategies that can improve antibiotic efficacy towards 
biofilms. ROS has been successful in treating chronic wounds and in clearing 
multidrug-resistant organisms, including methicillin-resistant Staphylococcus aureus 
(MRSA), and carbapenemase-producing isolates from wounds and vascular line 
sites. There is significant antifungal activity of ROS against planktonic and biofilm 
forms. Nebulised ROS has been evaluated in limited subjects to assess reductions in 
bioburden in chronically colonised respiratory tracts. The antibiofilm activity of ROS 
could have great implications for the treatment of a variety of persistent respiratory 
conditions. Use of ROS on internal prosthetic devices shows promise. A variety of 
novel delivery mechanisms are being developed to apply ROS activity to different 
anatomical sites. 
 
Keywords: 
Reactive oxygen species 
Biofilm 
Prosthetic device infection 
Cystic fibrosis 
Chronic wounds 
 
 
1. Introduction 
The overprescription and excessive consumption of antimicrobial agents worldwide 
has led to a near ‘post-antibiotic era’ due to the epidemic of antibiotic tolerance and 
resistant microbes. A World Health Organization (WHO) report on antimicrobial 
resistance highlights the gravity of the current epidemic as well as placing doubts on 
our future ability to treat common clinical infections [1]. The report also alludes to the 
increasing urgency in discovering novel antimicrobial therapeutic agents and 
developing fresh strategies in the fight against antimicrobial tolerance. 
 
We have previously reported the mechanism, safety and clinical applications (current 
and potential) for reactive oxygen species (ROS) therapy delivered as part of a 
symposium in Birmingham, UK in April 2016 [2]. ROS is the first entirely novel 
antimicrobial agent to reach early clinical use for several decades [3,4]. At present, 
ROS is available for clinical use in the form of Surgihoney Reactive Oxygen (SHRO), 
a natural honey with enhanced ROS activity, although there is a non-honey-based 
ROS gel due to be available for clinical use shortly. The clinical applications of ROS 
are topical, although ROS has also been used locally on internal structures and has 
the potential for other delivery mechanisms. 
 
ROS particularly lends itself to conditions of soft tissue and epithelial surfaces (e.g. 
respiratory, urinary) where there may be a heavy bacterial bioburden with biofilm and 
chronic inflammation. Bacterial biofilms are a significant problem in clinical settings 
by virtue of their increased tolerance towards conventionally prescribed antibiotics 
and their propensity to develop further antibacterial resistance. There is therefore a 
pressing need for the development of alternative therapeutic strategies that can 
improve antibiotic efficacy towards biofilms, thereby limiting antibiotic use and 
reducing the development of further resistance. 
 
This review reports the output of a national symposium in the UK that looked at the 
effect of ROS on microbial biofilms. This could have significant therapeutic 
implications because antibiotics are typically poorly effective in biofilm-associated 
conditions. ROS delivered through engineered honey, as a topical gel or through 
other delivery mechanisms (as described below) could provide effective therapy in a 
wide range of biofilm-associated conditions. 
 
2. Surgihoney Reactive Oxygen (SHRO) in wound biofilms 
SHRO has been evaluated in chronic wounds in an open-label, multicentre study 
and has been shown, through its ROS activity, to reduce bacterial bioburden and 
biofilm, to support healing [5] and to prevent surgical site infections [6]. A recent 
study investigated the ability of SHRO and ROS prototypes with increased 
antimicrobial activity (SH2 and SH3) to prevent biofilm formation in vitro by 16 
bacterial isolates [7]. For completeness, SHRO, SH2 and SH3 were compared with 
regularly used medical-grade honeys, including Activon manuka honey and 
Medihoney® manuka honey, as well as five antimicrobial dressings (AMDs). All of the 
honey products were serially double diluted in water from 1:3 down to 1:6144, and 
the lowest dilution achieving a statistically significant reduction in biomass of 50% 
compared with untreated controls was recorded. Although all of the honey products 
were antibacterial and were able to prevent the formation of biofilms, SHRO was the 
most potent, with efficacy at lower dilutions than the other medical honeys. In 
addition, SHRO was superior in antibacterial potency to three commercially available 
AMDs that contain honey. It was concluded that SHRO is effective at preventing 
biofilms from forming and is superior to medical honeys and AMDs in these in vitro 
tests [7]. 
 
This in vitro study lends weight to the findings of clinical studies. It is difficult to 
demonstrate biofilms in vivo, and the pathological role of bacterial biofilms in chronic 
soft tissue lesions is debated. However, chronic soft tissue lesions can become 
heavily colonised with bacteria and are difficult to treat since they respond poorly to 
conventional antibiotic treatment. This leads to poor healing and potential 
transmission of multidrug-resistant (MDR) bacteria. ROS therapy appears to be 
highly active against biofilms in vivo, clinically effective, and can spare conventional 
antibiotic use and support infection control [5–9]. 
 
3. Reactive oxygen species as a novel adjunctive biofilm-targeted 
therapy in chronic rhinosinusitis 
Chronic rhinosinusitis (CRS) is a common upper airway infectious condition affecting 
up to 11% of the European population [10] and is a prominent risk factor for asthma. 
It is the second most common chronic disease in the UK (after arthritis), occurring 
more frequently than heart disease or high blood pressure. Afflicted patients often 
require life-long medical treatments and surgery to re-open and ventilate the sinuses, 
facilitating improved medication delivery. It is estimated that these medical and 
surgical treatments cost the UK National Health Service in the region of £100 million 
per annum, placing a significant pressure on already overstretched resources. The 
impact of this disease is often underappreciated, with sufferers having a significantly 
impaired quality of life. CRS remains a difficult condition to control medically, with a 
significant number of patients requiring endoscopic sinus surgery [11]. It is well 
established that biofilm-positive CRS patients are likely to have increased infective 
exacerbations and slower wound healing and mucosal restoration rates, in addition 
to a higher level of antibiotic dependence [11]. Staphylococcus aureus biofilms in 
particular have been identified as one of the main causative agents for chronicity and 
recalcitrance of the disease [11–13]. 
 
The main aim of the project reported in this section was to investigate whether 
SHRO can be developed and repurposed for use as a novel biofilm-targeted and 
antibiotic-sparing therapy in CRS patients [14]. To evaluate this, in vitro biofilms 
formed by strains of methicillin-sensitive S. aureus (MSSA) isolated from CRS 
patients undergoing surgery were treated with SHRO for 24 h. Comparative analysis 
with untreated MSSA biofilms revealed that SHRO treatment caused a 2–3 log-fold 
reduction in the number of viable cells present in the biofilms (Fig. 1). 
 
These preliminary data suggest that SHRO represents a viable antimicrobial 
adjunctive therapy in S. aureus biofilm-associated CRS disease. In view of the 
current epidemic of antimicrobial resistance, this new treatment has the potential to 
reduce antibiotic use and to improve outcomes after endoscopic sinus surgery. 
 
4. Antibiofilm activity of Surgihoney Reactive Oxygen (SHRO) 
against non-typeable Haemophilus influenzae 
Otitis media, one of the most common infections in young children, is primarily 
caused by the opportunistic pathogens Streptococcus pneumoniae and non-typeable 
Haemophilus influenzae (NTHi). These infections are the principal reason for 
repeated physician visits, contribute towards a significant socioeconomic burden, 
and most importantly represent the primary reason for antibiotic prescription in young 
children [15–17]. Recent research has determined that biofilm formation by 
pneumococcus and NTHi plays an important role both in colonisation and disease. 
Subsequent investigations have since focused on developing a better understanding 
of how these biofilms enable survival in the nasopharyngeal niche. This has led to 
the identification of a subset of proteins that are differentially expressed when 
pneumococcus undergoes the transition from a planktonic phenotype to the 
formation of a biofilm [18]. Of particular interest is the >2-fold increase in expression 
of pyruvate oxidase (SpxB), an enzyme responsible for the production of 
extracellular hydrogen peroxide (H2O2). Production of this ROS confers 
pneumococcus a competitive advantage over other pathogens that share the same 
nasopharyngeal niche, including NTHi [19]. It is possible that through exploitation of 
this susceptibility towards H2O2 that the tolerance of NTHi biofilms to antibiotic 
treatment could be diminished, or may yet provide an avenue for the development of 
an alternative therapeutic strategy that dispenses with the need for antibiotic 
prescription. SHRO that generates low concentrations of H2O2 over a sustained 
period of time represents such a product. Preliminary studies have shown that 
treatment of in vitro NTHi biofilms with low concentrations of SHRO has proven more 
effective than the conventional antibiotic amoxicillin/clavulanic acid, highlighting its 
potential as a new strategy for targeting NTHI biofilm-associated infections. 
 
5. Fungicidal effect of Surgihoney Reactive Oxygen (SHRO) on 
Fusarium biofilms 
Chronic infections such as chronic wounds comprise 60–80% of infectious diseases 
in humans [20]. Colonisation of fungi in wounds is associated with the use of broad-
spectrum antibiotics [21]. In patients with cutaneous trauma, Fusarium spp. may 
invade or colonise the burn wound [22]. Formation of biofilms contributes to the 
severity and delayed healing of chronic wounds [23–25]. Moreover, it has been 
shown that in 45 of 915 samples, Fusarium spp. formed biofilms in chronic wound 
infections [26]. 
 
Biofilms within wound infections have been linked to the pathogenesis of wounds 
and associated with delayed wound healing [23–25]. Recently, it was reported that in 
a total of 208 of 915 samples, fungi were identified from wounds within a 4-month 
study period. One of the most abundant moulds was Fusarium spp. [22]. It was also 
reported that as a result of low metabolic activities of biofilms, micro-organisms in 
biofilm forms are more difficult to eliminate with conventional antimicrobial agents 
than planktonic forms [26]. 
 
To remove or inhibit the growth of biofilms within wounds, looking for an ideal and 
novel method and/or agent that is non-toxic, inexpensive, practical and with less side 
effects than antimicrobial agents has been an active area of research. SHRO is an 
agent that meets all of these criteria [14]. Given recent conﬁrmation of the presence 
of Fusarium bioﬁlms in wounds and their role in delayed wound healing, we designed 
a study to examine the in vitro effectiveness of different SHRO concentrations as 
well as the antifungals amphotericin B and natamycin against Fusarium planktonic 
and biofilm forms of growth using an XTT-based metabolic assay. In addition, the 
fungal cell wall biomarkers galactomannan (GM) and -1-3-D-glucan (BDG) were 
measured to identify the effect of SHRO on the components of fungal cell wall. The 
results revealed that SHRO at a concentration of 50% markedly reduced biofilm 
formation in both isolates after 24 h of exposure. After 48 h of treatment, SHRO was 
able to prevent biofilm development of Fusarium solani and Fusarium oxysporum at 
concentrations of 25% and 100%, respectively. High levels of GM and BDG were 
detected after exposure of the biofilms to SHRO, suggesting that after exposure to 
SHRO the Fusarium biofilms were disrupted and GM was released. In a previous 
study, release of GM after exposure of Aspergillus spp. (Aspergillus fumigatus and 
Aspergillus terreus) to fluconazole, amphotericin B, liposomal amphotericin B and 
itraconazole was investigated [27]. The results showed that both formulations of 
amphotericin B and itraconazole reduced the GM level at the lowest doses tested. 
However, high doses of fluconazole had negligible effect on GM release, but at a 
concentration of 128 mg/L fluconazole increased the GM level [27]. These 
differences may result from several mechanisms of action. In a similar way, BDG 
was released at high levels (>500 pg/mL) in our study, which was the upper limit of 
the assay. 
 
Different concentrations of SHRO reduced biofilm formation by both Fusarium spp. 
compared with control biofilms. This effect may largely depend on the density of 
biofilm formation. SHRO at a concentration of 50% was found to disrupt established 
Fusarium biofilm after 24 h. Amphotericin B and natamycin also show a significant 
reduction in Fusarium biofilm at concentrations of 2 mg/L and 4 mg/L respectively. In 
contrast, for the planktonic form, concentrations of SHRO ranging from 25% to 50% 
had an effective minimum inhibitory concentration (MIC) against Fusarium planktonic 
cells. Both isolates were more susceptible to amphotericin B (1–2 mg/L) than 
natamycin (2–4 mg/L). The specific mechanism for releasing high GM and BDG after 
SHRO exposure cannot be explained without additional investigation. This is the first 
study reporting results of the effect of SHRO on the development of Fusarium 
biofilms as well as planktonic growth forms. It is also the first study examining the 
release of fungal biomarkers (GM and BDG) by Fusarium biofilms after exposure to 
SHRO and antifungal agents. 
 
6. Innovative reactive oxygen species delivery systems 
Currently, ROS is only available for clinical use as SHRO packaged in a sachet 
owing to its high viscosity. An ROS gel with the same efficacy, not using honey as a 
delivery mechanism, will be available shortly. The viscosity of SHRO can make it 
difficult to handle and to administer a controlled dose. Development of other physical 
formulations, which facilitate an application-specific release profile of ROS, is of 
great interest and could have wide clinical applications. It is conceivable that a 
carrier mechanism could be developed to deliver ROS at remote clinical sites. 
 
When developing such a system, it is important to consider the underlying 
mechanisms of action. In the case of SHRO, addition of external water activates the 
production of hydrogen peroxide and reactive oxygen (Eq. 1). As a consequence, a 
non-aqueous vehicle is required to avoid premature production of ROS before 
clinical application. Formulation of a non-aqueous product, in an appropriate physical 
form, would enable it to be stored and activated in situ. Owing to the wide range of 
bacterial species that SHRO is active against, there is a wide array of clinical 
applications in which it could be used. To date, much of the clinical use of SHRO has 
been topical. Therefore, initially this work has been focused on re-engineering what 
is currently in a sachet to a nebulisable spray, improving the ease of use and 
allowing for tailored release by altering the underlying formulation. 
 
C6H12O6  +  H2O + O2  
GOx 
→   C6H12O7  + H2O2  
 
Eq. 1. Oxidation of glucose by glucose oxidase to produce gluconic acid and 
hydrogen peroxide [28]. 
 
An emulsion can be defined as a dispersion of droplets of one liquid in another in 
which it is not soluble or miscible [29]. Emulsions come in two basic forms, oil in 
water and water in oil. Every-day examples of emulsions include salad dressing, 
paint and cosmetics. To create an emulsion that is stable over time, surfactants, 
otherwise known as emulsifiers, are often used [30]. Surfactants are molecules that 
exhibit a hydrophilic head and a hydrophobic tail, which enables them to reduce the 
surface tension between phases in an emulsion, providing stability. In a solution 
containing a water phase and an oil phase, they orientate themselves with the head 
of the surfactant in the water phase and with the tail in the oil phase. This creates 
droplets of one liquid within another; the formation of water droplets within an oil 
phase is referred to as a reverse micelle (Fig. 2). 
 During the formulation of an emulsion, a shear force is typically applied to the 
continuous phase before addition of the dispersed phase. This allows for the 
generation of small droplets of the dispersed phase. Using a cup and vane set-up on 
an AR-G2 rheometer (TA Instruments, UK), the influence of temperature and shear 
rate on the efficacy of SHRO was established prior to emulsion formulation. The use 
of this geometry allowed for homogeneous control of temperature and shear rate. 
 
A range of oils and surfactants were investigated with the aim of achieving a stable 
non-aqueous emulsion in which SHRO was encapsulated within reverse micelles. 
Promisingly, these initial studies demonstrated that it was possible to produce a 
stable formulation when SHRO was encapsulated by reverse micelles in paraffin oil 
(Fig. 2). This was achieved by using polyglycerol polyricinoleate (PGPR) as a 
surfactant. Importantly, the emulsion maintained its capacity to generate ROS when 
stored under ambient conditions (20 C) for up to 4 weeks. Size analysis of the 
reverse micelles using optical microscopy revealed an average of 180 m, however 
this was observed to vary significantly from 65 m to 400 m throughout the samples 
(Fig. 3). It is suggested that the size heterogeneity may have occurred as a result of 
coalescence of the micelles; this is where two or more particles may combine due to 
interface instability. This process may continue over time and is irreversible [31]. To 
address this, future studies will investigate producing a smaller and narrower 
distribution of particles, which ultimately will improve longevity and delivery. 
 
Fundamentally, the rheology of this initial promising formulation may be modified to 
match that of a cream or spray; both of these physical forms would improve the ease 
of application clinically. To demonstrate this potential, the emulsion was loaded into 
a pump spray bottle and manually nebulised (Fig. 4). This spray was directed into a 
beaker and was tested for the presence of peroxides both before and after the 
addition of water using Quantofix® peroxide test sticks (Sigma-Aldrich, UK). The test 
showed that before addition of water, peroxides were not produced and after addition 
peroxides were detected, as demonstrated by the blue colour of test stick ii in Fig. 4. 
 
The outputs of this preliminary study demonstrate the ability to exploit formulation 
engineering to develop innovative ROS products that may be used as alternatives to 
current antibiotic-based treatments. Such research has the potential to address a 
number of unmet clinical needs. Notably, these innovations are timely to aid in the 
fight against antimicrobial resistance. 
 
7. Conclusions 
An earlier review reported on this novel ROS technology, the mechanism of action 
and potential therapeutic applications [1]. This review has examined in more detail 
the effects of ROS therapy on microbial biofilms. Biofilms in association with heavy 
microbial bioburden cause persistent infection in many clinical conditions. Most of 
these infections result from initial colonisation and have a connection to the exterior: 
wounds, burns, inflamed respiratory tract or bladder mucosa. Bioburden and biofilm 
cause significant pathology in these conditions, and conventional antibiotics are 
poorly active against biofilm-associated infection. Indeed, antibiotics in these 
conditions tend to result in greater antimicrobial resistance through selection 
pressure. 
 
ROS has been successful in treating chronic wounds [4] and clearing MDR 
organisms, including methicillin-resistant S. aureus (MRSA), and carbapenemase-
producing isolates from wounds and vascular line sites [7,8]. The significant 
antifungal activity of ROS on planktonic and biofilm-based microbes is documented 
in Section 5. Nebulised ROS has been evaluated in limited subjects to assess 
reductions in bioburden in chronically colonised respiratory tracts [14]. The work 
outlined in Sections 3 and 4 on the effects of SHRO on respiratory tract mucosa 
could have great implications for the treatment of a variety of persistent respiratory 
conditions. These are just the sort of conditions where conventional antibiotics are 
overused with limited clinical benefit and where ROS could play an important role in 
control of bioburden and biofilm. ROS technology could help patients with chronic 
colonisation and infection of the bladder with MDR bacteria. 
 
Finally, research into ROS delivery formats is important to enable the delivery of 
active ROS to remote sites of infection while retaining antimicrobial activity. This 
symposium may prove to have had historic implications by presenting the first 
entirely novel antimicrobial technology for several decades and a technology with 
wide clinical applications that will provide one solution to help resolve the global 
crisis of infections caused by MDR microbes. 
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Fig. 1. Surgihoney Reactive Oxygen (SHRO) treatment reduces the viability of 
methicillin-sensitive Staphylococcus aureus (MSSA) biofilms. In vitro 48-h-old 
biofilms formed by MSSA isolates from chronic rhinosinusitis patients were treated 
with SHRO for 24 h and viability was measured by enumeration of CFU. A significant 
reduction in viability (2–3 log-fold) was observed following treatment with SHRO. 
  
  
Fig. 2. Schematic illustrating (A) a surfactant molecule and (B) how they arrange to 
form a reverse micelle. 
  
  
Fig. 3. Micrographs of successful reverse micelles containing Surgihoney™RO® in a 
continuous phase of paraffin oil demonstrating the presence of (A) coalesced 
droplets and (B) smaller stable individual droplets. 
  
  
Fig. 4. (A) Surgihoney™RO® spray and (B) hydrogen peroxide test strips 
demonstrating no detectable concentration of peroxides before water addition (i) and 
production of ca. 3–10 ppm of detectable peroxides after water addition (ii). 
